MiniMed accelerates growth with pipeline milestones and higher FY27 guidance
MiniMed reported a strong Q1 FY27, with $843M in net sales and 16.6% growth (15.8% organic), led by 13% US and 18% international expansion. The company highlighted major pipeline milestones—FDA submission for MiniMed Fit and CE Mark for MiniMed Flex—alongside raised FY27 organic growth guidance of about 10.5% and ~16% EBITDA. The mix of accelerating growth, product advancement, and a higher guide could spur near-term upside for MMED shares.
View signal analysis